Akbarzadeh Khiavi Mostafa, Safary Azam, Somi Mohammad Hossein
Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, 51656-65811, Iran.
Bioimpacts. 2019;9(3):123-127. doi: 10.15171/bi.2019.16. Epub 2019 Mar 8.
Despite rapid advances in diagnostic and treatment approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading cause of neoplasm-related deaths worldwide, in large part due to its considerable metastasis and drug resistance. For developing new anticancer strategies, rapid progression of multimodal nanomedicines and nanoconjugates has provided promising treatment modalities for effective therapy of cancer. The limitations of cancer chemotherapy might be overcome through the use of such nanosized therapeutics, including nanoconjugates of monoclonal antibodies (mAbs) along with drugs and organic/inorganic nanoparticles. CRC cells express various molecular markers against which mAbs can be designed and used as targeting/therapeutic agents. This editorial highlights the importance of such targeted nanosystems against CRC.
尽管诊断和治疗方法取得了快速进展，但癌症的总体生存率并未得到改善。结直肠癌（CRC）被认为是全球肿瘤相关死亡的第三大主要原因，这在很大程度上归因于其显著的转移和耐药性。为了开发新的抗癌策略，多模态纳米药物和纳米缀合物的快速发展为癌症的有效治疗提供了有前景的治疗方式。通过使用此类纳米尺寸的治疗剂，包括单克隆抗体（mAb）与药物以及有机/无机纳米颗粒的纳米缀合物，可能克服癌症化疗的局限性。CRC细胞表达各种分子标志物，针对这些标志物可以设计mAb并用作靶向/治疗剂。这篇社论强调了此类针对CRC的靶向纳米系统的重要性。
